Tag Archives: hypertension

Merck Gets to the Heart of the Matter

Merck may have succeeded in making a molecule that increases “good cholesterol,” which is likely the only real breakthrough left in the anti-cholesterol and hypertension market. It has long been known that elevated LDL cholesterol and reduced HDL cholesterol are major risk factors for developing cardiovascular disease. And while much ado has been made about […]
Posted in News, Strategy | Also tagged , | 1 Comment

Statins Get Boost from New Study

Image via Wikipedia Statins should be given to people with high blood pressure or diabetes, even if they don’t have heart disease, according to a study published in the British Medical Journal. While several studies have shown that statins benefit those with cardiovascular disease, this is the first large study which looked at statins as […]
Posted in News, Strategy | Also tagged , , , , , , | Leave a comment

Strategic Patient Adherence Awards: “And the Winners Are”

Pharm Exec was proud to partner this year with CBI on the eighth annual Forum on Patient Compliance, Adherence & Persistency. One of the highlights of the event is the presentation of the Strategic Patient Adherence Awards, which honor pharma-based programs to improve compliance. The winners this year: For best branded program AstraZeneca Canada for […]
Posted in Events | Also tagged , , , , , , | Leave a comment

Gilead Buys CV Therapeutics (Update 1)

The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo Alto-based cardiovascular company CV Therapeutics from the hostile embrace of Astellas Pharma, ending a messy $1.1 billion takeover attempt. With the acquisition, Gilead, […]
Posted in Deals | Also tagged , , , , , , | 3 Comments
  • Categories

  • Meta